Avanir Pharmaceuticals, Inc. (AVNR) - Financial and Strategic SWOT Analysis Review

Document Sample
Avanir Pharmaceuticals, Inc. (AVNR) - Financial and Strategic SWOT Analysis Review Powered By Docstoc
					            Avanir Pharmaceuticals, Inc. (AVNR) - Financial and Strategic SWOT
                                     Analysis Review
        Reference Code: GDPH59410FSA                                                                                                                          Publication Date: JAN 2014

       Table of Contents
       Table of Contents ............................................................................................................................................................................... 1
          List of Tables .................................................................................................................................................................................. 3
          List of Figures ................................................................................................................................................................................. 3
       Section 1 - About the Company.......................................................................................................................................................... 5
       Avanir Pharmaceuticals, Inc. - Key Facts ........................................................................................................................................... 5
       Avanir Pharmaceuticals, Inc. - Key Employees .................................................................................................................................. 6
       Avanir Pharmaceuticals, Inc. - Key Employee Biographies ................................................................................................................ 7
       Avanir Pharmaceuticals, Inc. - Major Products and Services ............................................................................................................. 8
       Avanir Pharmaceuticals, Inc. - Pharmaceutical Pipeline Products Data ............................................................................................. 9
          Avanir Pharmaceuticals, Inc., Pipeline Products by Therapy Area ................................................................................................. 9
          Avanir Pharmaceuticals, Inc., Pipeline Products by Development Phase ..................................................................................... 10
       Avanir Pharmaceuticals, Inc. - History .............................................................................................................................................. 12
       Avanir Pharmaceuticals, Inc. - Company Statement ........................................................................................................................ 14
       Avanir Pharmaceuticals, Inc. - Locations And Subsidiaries .............................................................................................................. 17
          Head Office ................................................................................................................................................................................... 17
       Section 2 – Company Analysis ......................................................................................................................................................... 18
       Avanir Pharmaceuticals, Inc. - Business Description ....................................................................................................................... 18
       Avanir Pharmaceuticals, Inc. - Corporate Strategy........................................................................................................................... 19
       Avanir Pharmaceuticals, Inc. - SWOT Analysis ................................................................................................................................ 20
          SWOT Analysis - Overview........................................................................................................................................................... 20
          Avanir Pharmaceuticals, Inc. - Strengths ...................................................................................................................................... 20
             Strength - Sturdy Research and Development Activities ........................................................................................................... 20
             Strength - Strong Patent and Intellectual Property Protection ................................................................................................... 20
          Avanir Pharmaceuticals, Inc. - Weaknesses ................................................................................................................................. 20
             Weakness - Concentrated Geographical Presence .................................................................................................................. 20
             Weakness - Dependence on Third-Party .................................................................................................................................. 20
             Weakness - History of net losses .............................................................................................................................................. 21
          Avanir Pharmaceuticals, Inc. - Opportunities ................................................................................................................................ 21
             Opportunity - Product Pipeline .................................................................................................................................................. 21
             Opportunity - Strategic Agreements .......................................................................................................................................... 21
             Opportunity - Market Potential – CNS Therapy ......................................................................................................................... 21
             Opportunity - Changing Demographics ..................................................................................................................................... 22
             Opportunity - Emerging Markets ............................................................................................................................................... 22
          Avanir Pharmaceuticals, Inc. - Threats ......................................................................................................................................... 22
             Threat - Product Liability Claims ............................................................................................................................................... 22
             Threat - Increasing Counterfeit Products................................................................................................................................... 22
             Threat - Stringent Government Regulations .............................................................................................................................. 23
             Threat - Competitive Pressures ................................................................................................................................................. 23
       Avanir Pharmaceuticals, Inc. - Key Competitors .............................................................................................................................. 24
       Section 3 – Company Financial Ratios ............................................................................................................................................. 25
       Financial Ratios - Capital Market Ratios........................................................................................................................................... 25


Avanir Pharmaceuticals, Inc. (AVNR) - Financial and Strategic                                                                                                  Reference Code: GDPH59410FSA
SWOT Analysis Review
Source : www.globalcompanyintelligence.com                                                                                                                                                                Page 1
© GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form
       Financial Ratios - Annual Ratios ...................................................................................................................................................... 25
       Performance Chart ........................................................................................................................................................................... 27
       Financial Performance...................................................................................................................................................................... 27
       Financial Ratios - Interim Ratios....................................................................................................................................................... 28
       Financial Ratios - Ratio Charts ......................................................................................................................................................... 29
       Section 4 – Company’s Lifesciences Financial Deals and Alliances ................................................................................................ 30
          Avanir Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2008 to YTD 2014............................................... 30
          Avanir Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Type, 2008 to YTD 2014 .............................................. 31
       Avanir Pharmaceuticals, Inc., Recent Deals Summary .................................................................................................................... 32
       Section 5 – Company’s Recent Developments ................................................................................................................................ 33
          Avanir Pharmaceuticals, Inc., Recent Developments ................................................................................................................... 33
             Jan 13, 2014: Avanir Pharmaceuticals Pre-announces Preliminary Fiscal 2014 First Quarter Financial Information ............... 33
             Jan 06, 2014: Avanir Pharmaceuticals to Present at J.P. Morgan 32nd Annual Healthcare Conference.................................. 33
             Dec 10, 2013: Avanir Pharmaceuticals Reports Fiscal 2013 Fourth Quarter Financial and Year-End Business Results ......... 33
             Nov 26, 2013: Avanir Pharmaceuticals to Participate in Two Conferences in December.......................................................... 34
             Nov 08, 2013: Avanir Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)......................... 34
             Oct 29, 2013: Avanir Pharmaceuticals Pre-Announces Preliminary Fiscal 2013 Year End Financial Information .................... 35
             Oct 23, 2013: Avanir Pharmaceuticals to Host Investor Day on October 29, 2013 ................................................................... 35
             Oct 04, 2013: Avanir Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) ......................... 35
             Sep 04, 2013: Avanir Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)......................... 35
             Aug 22, 2013: Avanir Pharmaceuticals Announces Publication of 'PRISM' Pseudobulbar Affect Registry Findings................. 36
       Section 6 – Appendix .............................................................................................
				
DOCUMENT INFO
Description: Avanir Pharmaceuticals, Inc. (AVNR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better. The profile contains critical company information including: - Business description – A detailed description of the company’s operations and business divisions. - Corporate strategy – Analyst’s summarization of the company’s business strategy. - SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats. - Company history – Progression of key events associated with the company. - Major products and services – A list of major products, services and brands of the company. - Key competitors – A list of key competitors to the company. - Key employees – A list of the key executives of the company. - Executive biographies – A brief summary of the executives’ employment history. - Key operational heads – A list of personnel heading key departments/functions. - Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company. - Key manufacturing facilities – A list of key manufacturing facilities of the company. - Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history. - Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history. Highlights Avanir Pharmaceuticals, Inc. (Avanir) is a biopharmaceutical company. It acquires, deve
BUY THIS DOCUMENT NOW PRICE: $125 100% MONEY BACK GUARANTEED
PARTNER GlobalData
GlobalData is an industry analysis specialist, providing business information products and services. GlobalData’s highly qualified team of analysts, researchers, and solution consultants use proprietary data sources, tools and techniques to gather, analyze and represent the latest and the most reliable information essential for a business to sustain a competitive edge. GlobalData is a UK-based company with presence across North America, Europe and Asia Pacific and has a broad product offering that ranges from interactive databases, reports and custom solutions. It is a comprehensive source of insights and analysis with coverage across the oil & gas, power, alternative energy, nuclear power, petrochemicals, medical equipment and healthcare industries. GlobalData has a broad range of coverage over key market segments. It has a global scope, covering a wide range of countries constituting more than 90% of global revenues in each of the industries it covers. With a large dedicated research and analysis capability, GlobalData employs rigorous primary and secondary research techniques in developing unique data sets and research materials. Its status as an independent research company allows Analysts to conduct trade interviews with key industry players. Access to unique databases of in-house market information further strengthens research and analysis capabilities. Materials are reviewed shaped by an expert panel of leading industry figures and representatives from key players in the relevant industries. Sectors and Geographies Covered GlobalData has a broad range of coverage over key market segments. It has a global scope, covering a wide range of countries constituting more than 90% of global revenues in each of the industries it covers. Research Methodology With a large dedicated research and analysis capability, GlobalData employs rigorous primary and secondary research techniques in developing unique data sets and research materials. Its status as an independent research company allows Analysts to conduct trade interviews with key industry players. Access to unique databases of in-house market information further strengthens research and analysis capabilities. Materials are reviewed shaped by an expert panel of leading industry figures and representatives from key players in the relevant industries.